Bosnia and Herzegovina vs Ukraine: The number of people with susceptibility test result for rifampicin
Bosnia and Herzegovina
97.7
in 2021
Ukraine
97.48
in 2021
Bosnia and Herzegovina rank
38th
Ukraine rank
39th
The number of people with susceptibility test result for rifampicin over time
- Bosnia and Herzegovina
- Ukraine
How they compare
Bosnia and Herzegovina currently reports 97.7 against 97.48 in Ukraine, a difference of 0.22.
The two have swapped places 3 times across 5 shared years of data; in 2017 it was Ukraine ahead.
Bosnia and Herzegovina ranks 38th and Ukraine ranks 39th of 146 countries.
Across the 2 decades both report, Bosnia and Herzegovina averaged higher in 1 and Ukraine in 1.
Head to head by decade
| Decade | Bosnia and Herzegovina | Ukraine | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 93.68 | 95.6 | 1.92 | Ukraine |
| 2020s | 97.68 | 97.36 | 0.3149 | Bosnia and Herzegovina |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher the number of people with susceptibility test result for rifampicin, Bosnia and Herzegovina or Ukraine?
- Bosnia and Herzegovina, at 97.7 against 97.48 in Ukraine as of 2021.
- What is the difference in the number of people with susceptibility test result for rifampicin between Bosnia and Herzegovina and Ukraine?
- 0.22, with Bosnia and Herzegovina ahead.
- How many years of comparable data are there for Bosnia and Herzegovina and Ukraine?
- 5 years are reported by both, from 2017 to 2021.
- How do Bosnia and Herzegovina and Ukraine rank globally for the number of people with susceptibility test result for rifampicin?
- Bosnia and Herzegovina ranks 38th and Ukraine ranks 39th of 146 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.. Statizoid refreshes it automatically from the source and publishes the full history for both places.